Treatment
Dose Escalation clinical trials
We’re tracking 184 recruiting studies that include Dose Escalation, each written for real people, not researchers, below.
Recruiting studies
- NCT06975787RecruitingPhase 1
A New Bispecific Antibody for Lupus Nephritis
This trial is testing a new type of medicine called a 'bispecific antibody' for people whose lupus nephritis has not responded to standard treatments or keeps coming back. The goal is to find a safe dose that might better control the kidney inflammation.
San Francisco, CaliforniaAges 18–60 - NCT06980025RecruitingPhase 3
Aspirin dose trial to prevent preterm birth
This study tests if a higher dose of aspirin can help prevent another early delivery in women who have had a preterm birth before. If you qualify, you would take either a standard or escalated dose of aspirin during your current pregnancy.
Birmingham, AlabamaAges 14 years+ - NCT06835803RecruitingPhase 2
Intensified radiation for older adults with glioblastoma
This trial tests whether a more focused, stronger dose of radiation can improve outcomes for people 65 and older with newly diagnosed glioblastoma. It compares this approach to standard radiation to see if it's safe and effective.
Boston, MassachusettsAges 65 years+ - NCT06794125Recruiting
Higher radiation dose for chest tumors
This trial tests if giving a higher dose of radiation to tumors in the chest (lungs or nearby areas) can better control symptoms or prevent them from getting worse. It is for people who need palliative radiation—treatment aimed at easing discomfort or slowing tumor growth, not curing the cancer.
Kelowna, British ColumbiaAges 18 years+ - NCT06769490RecruitingPhase 1
Ziftomenib and Quizartinib combination for AML
This trial tests two targeted drugs, ziftomenib and quizartinib, together for people with a certain type of acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal is to find the best dose and see if the combination helps.
Houston, TexasAges 18 years+ - NCT06724016RecruitingPhase 1
Study of HM16390 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug, HM16390, either by itself or combined with pembrolizumab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find the best dose and see if it can shrink tumors.
Boston, MassachusettsAges 18 years+ - NCT06592638RecruitingPhase 1
ZG006 for small cell lung cancer
This trial tests a new drug called ZG006 for people with small cell lung cancer that has not responded to or can no longer tolerate standard treatments. The goal is to find the best dose and see if it can help shrink or control the cancer.
Orange, CaliforniaAges 18–75 - NCT06658535RecruitingPhase 1
Study of NanO2 for mild breathing problems
This trial tests an experimental drug called NanO2 for people with mild respiratory distress who need a small amount of extra oxygen. The goal is to see if it can help improve oxygen levels.
Edmonton, AlbertaAges 18 years+ - NCT06660420RecruitingPhase 1
PRAME-targeted NK cells for advanced melanoma
This trial tests a new type of cell therapy using your own immune cells (NK cells) modified to target a protein called PRAME found on melanoma cells. It is for people whose melanoma has not responded to or has returned after standard immunotherapies.
Houston, TexasAges 18 years+ - NCT06636032RecruitingPhase 1/Phase 2
Stem cells for Crohn's fistula treatment
This trial tests whether injecting donated stem cells into complex anal fistulas can help heal them in people with Crohn's disease. You may qualify if you have a fistula that hasn't improved with standard treatments.
ToulouseAges 18 years+ - NCT06446128RecruitingEarly Phase 1
CAR-T cell therapy for B-cell lymphoma that returned or didn't respond
This trial tests a new CAR-T treatment that targets three proteins on lymphoma cells (CD19, CD22, and BCMA). It is for people with certain types of B-cell lymphoma that have come back or are not responding to standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06625970RecruitingPhase 3
Darolutamide and high-dose radiation for high-risk prostate cancer
This trial tests a combination of a hormone therapy pill (darolutamide) and a high-dose, precise form of radiation for men with localized prostate cancer that has high-risk features of coming back. The goal is to see if this approach is more effective than standard treatment.
BrestAges 18–80 - NCT06596291RecruitingPhase 1/Phase 2
Study of an injected treatment for bladder control after spinal cord injury
This trial tests a new medication injected directly into the bladder muscle to help reduce urine leakage in people with spinal cord injuries. It is for those who have tried other treatments without enough success and are considering more invasive options.
Downey, CaliforniaAges 18–75 - NCT05490888RecruitingPhase 1
Dose study of PHIN-214 for mild to moderate cirrhosis
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Chandler, ArizonaAges 18–75 - NCT06476808RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an investigational drug (BMS-986463) in people with advanced solid tumors. It aims to find a safe dose and see if it helps shrink or control the cancer. You must be well enough to do daily activities and have a tumor that can be biopsied before treatment starts.
Los Angeles, CaliforniaAges 18 years+ - NCT05055609RecruitingPhase 1
Study drug TRE-515 for advanced solid tumors using PET scans
This Phase 1 trial tests how safe TRE-515 is, what dose can be used, and how the drug moves through the body, including using PET scans. It’s for adults with advanced solid cancers that have stopped responding to standard treatment.
Santa Monica, CaliforniaAges 18 years+ - NCT06416007RecruitingPhase 2
Lattice radiation for large tumor palliation
This study tests a new way to deliver radiation called lattice therapy for people with large solid tumors that are causing symptoms. It aims to give a stronger radiation dose to help shrink the tumor and relieve discomfort.
Cincinnati, OhioAges 18 years+ - NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06328712RecruitingPhase 1/Phase 2
Cell therapy for Charcot-Marie-Tooth type 1A (CMT1A)
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
GyeongjuAges 19 years+ - NCT06310967RecruitingPhase 1/Phase 2
Study of IG3018 for high uric acid with or without kidney disease
This trial tests a new medicine, IG3018, to lower high uric acid levels in people with or without chronic kidney disease. It aims to find the right dose and see if it's safe.
Botany, New South WalesAges 18–75 - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Antioch, CaliforniaAges 18 years+ - NCT06234397RecruitingPhase 1
Study of BH3120 with or without pembrolizumab for advanced solid tumors
This trial is testing a new drug, BH3120, that boosts the immune system's ability to fight cancer. It's for people with advanced solid tumors that haven't responded to standard treatments. The drug may be given alone or with another immunotherapy drug called pembrolizumab.
Tampa, FloridaAges 18 years+ - NCT06238401RecruitingPhase 1
Testing ACR246 for advanced solid tumors
This trial tests a new drug called ACR246 for people with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see if the drug can shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT06239272RecruitingPhase 1/Phase 2
Personalized treatment for NRSTS in children and young adults
This trial tests a personalized treatment plan for children and young adults with a type of soft tissue sarcoma (NRSTS). It uses a combination of surgery, targeted radiation, and two drugs (pazopanib and selinexor) to fight cancer while reducing side effects. The study is looking for people who have not been treated before for this sarcoma.
Atlanta, GeorgiaAges Up to 30 years
Common questions
- Are there clinical trials studying Dose Escalation?
- Yes. Clin2 currently lists 184 recruiting studies that include Dose Escalation, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dose Escalation trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dose Escalation an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dose Escalation or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.